Delcath issues 2025 revenue guidance of $94-98M, plans to enter Medicaid drug rebate agreement

DELCATH SYSTEMS, INC.

Revenue guidance $94-98M, >150% YoY growth.
Gross margin 83-85%; positive adjusted EBITDA and cash flow each quarter in 2025.
Plans to enter NDRA with CMS, effective Q3 2025, expanding Medicaid/340B access.
CEO expects HEPZATO treatment volume to increase at least 200% in 2025 vs 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.